Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial

  1. Delforge, M.
  2. Otero, P.R.
  3. Shah, N.
  4. Moshkovich, O.
  5. Braverman, J.
  6. Dhanda, D.S.
  7. Lanar, S.
  8. Devlen, J.
  9. Miera, M.
  10. Gerould, H.
  11. Campbell, T.B.
  12. Munshi, N.C.
Revue:
Leukemia Research

ISSN: 1873-5835,  0145-2126

Année de publication: 2023

Volumen: 129

Type: Article

DOI: 10.1016/J.LEUKRES.2023.107074 GOOGLE SCHOLAR lock_openAccès ouvert editor
La source de données: Scopus